Copyright
©The Author(s) 2021.
World J Hepatol. Sep 27, 2021; 13(9): 1042-1057
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1042
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1042
Baseline at pretreatment | On-treatment | End of treatment |
Virological relapse | ||
High age[40,44] | Short consolidation duration[38] | High HBsAg level[40,41] |
Male sex[40] | High HBcrAg level[12] | |
High HBsAg level[44] | High HBV RNA level[12] | |
Clinical relapse | ||
High HBsAg level[44] | Short consolidation duration[44] | High HBsAg level[13,40,41] |
High HBcrAg level[12,13,52] | ||
High HBV RNA level[12,52] |
- Citation: Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057
- URL: https://www.wjgnet.com/1948-5182/full/v13/i9/1042.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i9.1042